Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Status:
Completed
Trial end date:
2016-07-28
Target enrollment:
Participant gender:
Summary
Summary:
The investigators propose a randomized controlled open label study of teriparatide in men or
women with rheumatoid arthritis and joint erosions. Specifically, the investigators will
examine whether teriparatide in combination with a biologic can retard the development of
joint erosions. The study will be conducted at Brigham and Women's Hospital Arthritis Center,
several Brigham and Women's Hospital Arthritis Center satellite practices, the University of
Massachusetts Medical Center, and Massachusetts General Hospital.
Hypothesis:
The investigators hypothesize that the combination of teriparatide with biologic will be much
more effective at retarding erosion progression then a biologic alone.
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Eli Lilly and Company
Treatments:
Calcium Teriparatide Tumor Necrosis Factor Inhibitors Vitamin D